Streetwise Reports' Article Archives — May 2021 back to current month (19)
Second-quarter clinical events related to Anavex Life Sciences' pipeline are summarized in a Dawson James Securities report.
Data from two of Oncternal Therapeutics' clinical trials in oncological indications are discussed in an H.C. Wainwright & Co. report.
Verastem Inc. shares reached a new 52-week high after the company reported its VS-6766 in combination with defactinib was granted breakthrough therapy designation by the FDA for treatment of recurrent low-grade serous ovarian cancer.
Updates on Aptinyx's three central nervous system drug candidates and the company's Q1/21 earnings are delivered in an H.C. Wainwright & Co. report.
Analyst Highlights Two Key Catalysts for Biotech (05/19/2021)
The biopharma aTyr's upcoming drug application and clinical-trial results are discussed in a ROTH Capital Partners report.
Sarepta Therapeutics shares traded 8% higher after the company reported its investigational gene therapy SRP-9001, used for treating Duchenne's Muscular Dystrophy, had "positive 12-week expression and safety results."
Shares of Apellis Pharmaceuticals Inc. traded 20% higher after the company reported it received U.S. FDA approval for EMPAVELI (pegcetacoplan) for use in treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic life-threatening blood disorder.
An H.C. Wainwright & Co. report discusses Gritstone Bio's recent earnings and significant corporate events as the firm plans to release data on cancer and COVID-19 vaccines later this year.
Algernon Pharmaceuticals reported that Ifenprodil was shown to reduce interleukin 6 in its Phase 2b/3 COVID-19 Study, which the company states may have positive implications for its use in its ongoing Phase 2 trial of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough.
Multiplan Corp. shares traded 17% higher after the company reported Q1/21 net income of $45.9 million, compared to a net loss of $2.6 million in the corresponding quarter last year.
Noble Capital Markets noted in a research report that shortly after receiving its largest single order to date, a 4.4-ton order for OxC-beta Livestock, Avivagen Inc. has received a new order for 4 tons per month from its representative in Mexico.
Second Sight Medical Products Inc. shares traded 25% higher after the company reported the results from a two-year study of its Orion Visual Cortical Prosthesis System.
Soliton Inc. shares traded 25% higher after the company reported it had agreed to be acquired by AbbVie Inc.'s Allergan Aesthetics for $22.60 per share in an all cash transaction.
COVID-19 brought record-setting investment to the healthcare industry in 2020, but this year is shaping up to be even better, reports McAlinden Research Partners. Demand for telehealth services skyrocketed during the pandemic, and funding is starting to follow suit.
Reliq Health Technologies reported the addition of four new skilled nursing facility customers in the southern U.S. and announced plans to expand its Care Management Team to meet the growing demand for Care Management Services.
Shares of Twist Bioscience Corp. traded 14% higher after the firm reported that orders in Q2/21 grew by 69% year-over-year and that it is raising its FY/21 revenue guidance to $121–129 million.
Sio Gene Therapies' focus and strategic portfolio are discussed in an H.C. Wainwright & Co. coverage initiation report.
Novamind Inc. is opening four new psychedelic mental health clinics as part of the company's national expansion strategy, giving it the capability to conduct 65,000 client visits in 2021.
BioNTech shares established a new 52-week high price after the company reported that together with its partner Pfizer it has filed a request to expand Conditional Marketing Authorization of COMIRNATY® in the EU to adolescents ages 12 to 15 for its mRNA-based SARS-CoV-2 vaccine.
|"Experiments showed that PMN's PMN310 has a unique binding profile."|